Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm InfantsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how a one week course of empirical antibiotics affects early gut microbiota and metabolites in preterm infants.
How was it studied?
Stool microbiota and metabolites were analyzed in 36 preterm babies split into three groups. Two groups received seven days of either penicillin plus moxalactam or piperacillin-tazobactam, and one group received no antibiotics.
What did they find?
Both antibiotic-treated groups showed reduced bacterial diversity and enrichment of harmful bacteria such as Streptococcus and Pseudomonas compared to the antibiotic-free group. Gut microbiota and metabolite composition also differed between the two antibiotic regimens, with piperacillin-tazobactam treatment linked to an overgrowth of Enterococcus.
Why it matters
Prolonged empirical antibiotic therapy disrupts early gut microbiota development in preterm infants. This should factor into antibiotic prescribing decisions for this vulnerable population.